Skip to main content
. 2016 Apr 26;7(22):32731–32753. doi: 10.18632/oncotarget.9022

Figure 5. Forest plots for multivariable analyses in the entire cohort.

Figure 5

TP53 mutations and p53 protein expression were included in all models. p53 IHC positivity was unfavorable in HER2-positive patients not treated but favorable in those treated with trastuzumab.